NewKI

• Research type

  Research Study

• Full title

  New onset of kidney impairment study

• IRAS ID

  230136

• Contact name

  Richard Hobbs

• Contact email

  richard.hobbs@phc.ox.ac.uk

• Sponsor organisation

  University of Oxford

• Duration of Study in the UK

  2 years, 0 months, 1 days

• Research summary

  Kidney function declines slowly with age and reduced kidney function is termed chronic kidney disease (CKD). Around 1 in 10 people have mild CKD. Although only a small proportion of this group will progress to severe kidney disease requiring dialysis or transplantation, CKD also puts people at high risk of cardiovascular disease, in particular stroke, heart failure and sudden death. Even people with very mild CKD have premature stiffening and reduced function of their heart and major arteries. Although CKD is recognised as an increasing problem there have been relatively few studies describing the people who have been diagnosed with the disease.
  Furthermore, alternative renal biomarkers may have greater accuracy for cardiovascular risk stratification but their predictive role as assessed in prospective studies has not been established.
  The Oxford Renal Study (OxRen) recruited participants over 60 years of age in a primary care population from November 2013 and closed for recruitment in March 2017, collecting data on prevalence of CKD. It was the largest national CKD observational study and we would like use the OxRen cohort to recruit for the NewKI study.
  As part of the OxRen study, patients who were diagnosed with CKD received annual follow-up to monitor disease progression, and some of those without CKD were re-screened after two years to collect data on incidence. We would like to make the most of the OxRen cohort primarily to understand the progression of CKD stages. We also want to be able to use this cohort of participants as a basis for re-screening patients without CKD who have not been rescreened for two years or longer, in order to answer the question of incidence of CKD in a demographic representative of the UK population. This study allows the collection of additional data to determine incidence of CKD, monitor disease progression, and identify markers associated with rapid progression as well as morbidity and mortality outcomes.

  The study will be supported by the Primary Care Clinical Trials Unit (PC CTU), an NIHR accredited CTU.

• REC name

  Yorkshire & The Humber - Bradford Leeds Research Ethics Committee

• REC reference

  17/YH/0429

• Date of REC Opinion

  8 Dec 2017

• REC opinion

  Favourable Opinion